# Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

> **NCT00044668** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 155 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** AC2993

## Key facts

- **NCT ID:** NCT00044668
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2015-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044668, "Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00044668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*